Must-read news from the week of November 14-18, 2022

Congenital hypopigmented macules on a healthy child

You are asked to evaluate an African American boy aged 4 years with a birthmark on his back and right arm. He is healthy with normal growth and development. What's the diagnosis?

How the FDA prevents drug shortages

At ACR Convergence 2022, Hyun Son, PharmD, discussed the role of the FDA’s Drug Shortage Staff in preventing and mitigating drug shortages.

VTAMA effective against pediatric atopic dermatitis

Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.

Updates on FDA drug approvals

At ACR Convergence 2022, Amit Golding, MD, PhD, outlined drugs recently approved by the FDA, and discussed the requirements for biosimilars to meet approval.

Roflumilast cream safe, effective for atopic dermatitis in children 6 years and up

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

Juvenile idiopathic inflammatory myopathies after COVID-19 infection

In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.

Increased neurologic involvement from COVID-19 in 2021

In a recent study, investigators found that life-threatening neurologic conditions from severe acute COVID-19 were more frequent in 2021 than 2020.